Literature DB >> 25324403

Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.

Tasuku Mariya1, Yoshihiko Hirohashi2, Toshihiko Torigoe2, Takuya Asano3, Takafumi Kuroda3, Kazuyo Yasuda4, Masahito Mizuuchi3, Tomoko Sonoda5, Tsuyoshi Saito6, Noriyuki Sato4.   

Abstract

Epithelial ovarian cancer (EOC) is one of the most deadly carcinomas in females. Immune systems can recognize EOCs; however, a defect of human leukocyte antigen (HLA) class I expression is known to be a major mechanism for escape from immune systems, resulting in poor prognosis. The purpose of this study is to identify novel correlations between immunologic responses and other clinical factors. We investigated the expression of immunologic components in 122 cases of EOCs for which surgical operations were performed between 2001 and 2011. We immunohistochemically stained EOC specimens using an anti-pan HLA class I monoclonal antibody (EMR8-5) and anti-CD3, -CD4, and -CD8 antibodies, and we analyzed correlations between immunologic parameters and clinical factors. In multivariate analysis that used the Cox proportional hazards model, independent prognostic factors for overall survival in advanced EOCs included low expression level of HLA class I [risk ratio (RR), 1.97; 95% confidence interval (CI), 1.01-3.83; P = 0.046] and loss of intraepithelial cytotoxic T lymphocyte (CTL) infiltration (RR, 2.11; 95% CI, 1.06-4.20; P = 0.033). Interestingly, almost all platinum-resistant cases showed a significantly low rate of intraepithelial CTL infiltration in the χ(2) test (positive vs. negative: 9.0% vs. 97.7%; P < 0.001). Results from a logistic regression model revealed that low CTL infiltration rate was an independent factor of platinum resistance in multivariate analysis (OR, 3.77; 95% CI, 1.08-13.12; P = 0.037). Platinum-resistant EOCs show poor immunologic responses. The immune escape system of EOCs may be one of the mechanisms of platinum resistance. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25324403     DOI: 10.1158/2326-6066.CIR-14-0101

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  26 in total

Review 1.  The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.

Authors:  André Steven; Barbara Seliger
Journal:  Breast Care (Basel)       Date:  2018-02-02       Impact factor: 2.860

2.  HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.

Authors:  J Brian Szender; Kevin H Eng; Junko Matsuzaki; Anthony Miliotto; Sacha Gnjatic; Takemasa Tsuji; Kunle Odunsi
Journal:  Gynecol Oncol       Date:  2016-04-23       Impact factor: 5.482

3.  HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer.

Authors:  Yoshihiko Hirohashi; Toshihiko Torigoe; Tasuku Mariya; Vitaly Kochin; Tsuyoshi Saito; Noriyuki Sato
Journal:  Oncoimmunology       Date:  2015-03-23       Impact factor: 8.110

Review 4.  Cancer treatment and the KIR-HLA system: an overview.

Authors:  Patrizia Leone; Valli De Re; Angelo Vacca; Franco Dammacco; Vito Racanelli
Journal:  Clin Exp Med       Date:  2017-02-10       Impact factor: 3.984

Review 5.  The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.

Authors:  Samuel A Funt; Paul B Chapman
Journal:  Clin Cancer Res       Date:  2016-02-03       Impact factor: 12.531

6.  CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.

Authors:  Holger Bronger; Judith Singer; Claudia Windmüller; Ute Reuning; Daniela Zech; Claire Delbridge; Julia Dorn; Marion Kiechle; Barbara Schmalfeldt; Manfred Schmitt; Stefanie Avril
Journal:  Br J Cancer       Date:  2016-08-04       Impact factor: 7.640

Review 7.  Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy.

Authors:  Terufumi Kubo; Tomoyo Shinkawa; Yasuhiro Kikuchi; Kenji Murata; Takayuki Kanaseki; Tomohide Tsukahara; Yoshihiko Hirohashi; Toshihiko Torigoe
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

Review 8.  Immune responses to human cancer stem-like cells/cancer-initiating cells.

Authors:  Yoshihiko Hirohashi; Toshihiko Torigoe; Tomohide Tsukahara; Takayuki Kanaseki; Vitaly Kochin; Noriyuki Sato
Journal:  Cancer Sci       Date:  2015-11-12       Impact factor: 6.716

9.  Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.

Authors:  Takuya Asano; Yoshihiko Hirohashi; Toshihiko Torigoe; Tasuku Mariya; Ryota Horibe; Takafumi Kuroda; Yuta Tabuchi; Hiroshi Saijo; Kazuyo Yasuda; Masahito Mizuuchi; Akari Takahashi; Hiroko Asanuma; Tadashi Hasegawa; Tsuyoshi Saito; Noriyuki Sato
Journal:  Oncotarget       Date:  2016-03-08

10.  Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37.

Authors:  Shi-xiong Ding; Jian-bo Ma; Yao-ren Hu; Ai-rong Hu; Qiang Shen; Guo-shen Gao
Journal:  Med Sci Monit       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.